TY - JOUR AU - Giacomini, K. M. AU - Brett, C. M. AU - Altman, R. B. AU - Benowitz, N. L. AU - Dolan, M. E. AU - Flockhart, D. A. PY - 2007 DA - 2007// TI - The pharmacogenetics research network: from SNP discovery to clinical drug response JO - Clin Pharmacol Ther VL - 81 UR - https://doi.org/10.1038/sj.clpt.6100087 DO - 10.1038/sj.clpt.6100087 ID - Giacomini2007 ER - TY - JOUR AU - Slamon, D. J. AU - Leyland-Jones, B. AU - Shak, S. AU - Fuchs, H. AU - Paton, V. AU - Bajamonde, A. PY - 2001 DA - 2001// TI - Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 JO - N Engl J Med VL - 344 UR - https://doi.org/10.1056/NEJM200103153441101 DO - 10.1056/NEJM200103153441101 ID - Slamon2001 ER - TY - JOUR AU - Ewer, M. S. AU - Vooletich, M. T. AU - Durand, J. B. AU - Woods, M. L. AU - Davis, J. R. AU - Valero, V. PY - 2005 DA - 2005// TI - Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment JO - J Clin Oncol VL - 23 UR - https://doi.org/10.1200/JCO.2005.13.300 DO - 10.1200/JCO.2005.13.300 ID - Ewer2005 ER - TY - JOUR AU - Seidman, A. AU - Hudis, C. AU - Pierri, M. K. AU - Shak, S. AU - Paton, V. AU - Ashby, M. PY - 2002 DA - 2002// TI - Cardiac dysfunction in the trastuzumab clinical trials experience JO - J Clin Oncol VL - 20 UR - https://doi.org/10.1200/JCO.20.5.1215 DO - 10.1200/JCO.20.5.1215 ID - Seidman2002 ER - TY - JOUR AU - Chen, T. AU - Xu, T. AU - Li, Y. AU - Liang, C. AU - Chen, J. AU - Lu, Y. PY - 2011 DA - 2011// TI - Risk of cardiac dysfunction with trastuzumab in breast cancer patients: a meta-analysis JO - Cancer Treat Rev VL - 37 UR - https://doi.org/10.1016/j.ctrv.2010.09.001 DO - 10.1016/j.ctrv.2010.09.001 ID - Chen2011 ER - TY - JOUR AU - Crone, S. A. AU - Zhao, Y. Y. AU - Fan, L. AU - Gu, Y. AU - Minamisawa, S. AU - Liu, Y. PY - 2002 DA - 2002// TI - ErbB2 is essential in the prevention of dilated cardiomyopathy JO - Nat Med VL - 8 UR - https://doi.org/10.1038/nm0502-459 DO - 10.1038/nm0502-459 ID - Crone2002 ER - TY - JOUR AU - Ozcelik, C. AU - Erdmann, B. AU - Pilz, B. AU - Wettschureck, N. AU - Britsch, S. AU - Hubner, N. PY - 2002 DA - 2002// TI - Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy JO - Proc Natl Acad Sci U S A VL - 99 UR - https://doi.org/10.1073/pnas.122249299 DO - 10.1073/pnas.122249299 ID - Ozcelik2002 ER - TY - JOUR AU - Lee, K. F. AU - Simon, H. AU - Chen, H. AU - Bates, B. AU - Hung, M. C. AU - Hauser, C. PY - 1995 DA - 1995// TI - Requirement for neuregulin receptor erbB2 in neural and cardiac development JO - Nature VL - 378 UR - https://doi.org/10.1038/378394a0 DO - 10.1038/378394a0 ID - Lee1995 ER - TY - JOUR AU - Zambelli, A. AU - Della Porta, M. G. AU - Eleuteri, E. AU - De Giuli, L. AU - Catalano, O. AU - Tondini, C. PY - 2011 DA - 2011// TI - Predicting and preventing cardiotoxicity in the era of breast cancer targeted therapies. Novel molecular tools for clinical issues JO - Breast VL - 20 UR - https://doi.org/10.1016/j.breast.2010.11.002 DO - 10.1016/j.breast.2010.11.002 ID - Zambelli2011 ER - TY - JOUR AU - Telli, M. L. AU - Hunt, S. A. AU - Carlson, R. W. AU - Guardino, A. E. PY - 2007 DA - 2007// TI - Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility JO - J Clin Oncol VL - 25 UR - https://doi.org/10.1200/JCO.2007.11.0106 DO - 10.1200/JCO.2007.11.0106 ID - Telli2007 ER - TY - JOUR AU - Montgomery, K. G. AU - Gertig, D. M. AU - Baxter, S. W. AU - Milne, R. L. AU - Dite, G. S. AU - McCredie, M. R. PY - 2003 DA - 2003// TI - The HER2 I655V polymorphism and risk of breast cancer in women < age 40 years JO - Cancer Epidemiol Biomarkers Prev VL - 12 ID - Montgomery2003 ER - TY - JOUR AU - Rutter, J. L. AU - Chatterjee, N. AU - Wacholder, S. AU - Struewing, J. PY - 2003 DA - 2003// TI - The HER2 I655V polymorphism and breast cancer risk in Ashkenazim JO - Epidemiology VL - 14 UR - https://doi.org/10.1097/01.ede.0000083227.74669.7b DO - 10.1097/01.ede.0000083227.74669.7b ID - Rutter2003 ER - TY - JOUR AU - Han, X. AU - Diao, L. AU - Xu, Y. AU - Xue, W. AU - Ouyang, T. AU - Li, J. PY - 2014 DA - 2014// TI - Association between the HER2 Ile655Val polymorphism and response to trastuzumab in women with operable primary breast cancer JO - Ann Oncol VL - 25 UR - https://doi.org/10.1093/annonc/mdu111 DO - 10.1093/annonc/mdu111 ID - Han2014 ER - TY - JOUR AU - Han, W. AU - Kang, D. AU - Lee, J. E. AU - Park, I. A. AU - Choi, J. Y. AU - Lee, K. M. PY - 2005 DA - 2005// TI - A haplotype analysis of HER-2 gene polymorphisms: association with breast cancer risk, HER-2 protein expression in the tumor, and disease recurrence in Korea JO - Clin Cancer Res VL - 11 UR - https://doi.org/10.1158/1078-0432.CCR-04-2208 DO - 10.1158/1078-0432.CCR-04-2208 ID - Han2005 ER - TY - JOUR AU - Xie, D. AU - Shu, X. O. AU - Deng, Z. AU - Wen, W. Q. AU - Creek, K. E. AU - Dai, Q. PY - 2000 DA - 2000// TI - Population-based, case–control study of HER2 genetic polymorphism and breast cancer risk JO - J Natl Cancer Inst VL - 92 UR - https://doi.org/10.1093/jnci/92.5.412 DO - 10.1093/jnci/92.5.412 ID - Xie2000 ER - TY - JOUR AU - Beauclair, S. AU - Formento, P. AU - Fischel, J. L. AU - Lescaut, W. AU - Largillier, R. AU - Chamorey, E. PY - 2007 DA - 2007// TI - Role of the HER2 [Ile655Val] genetic polymorphism in tumorogenesis and in the risk of trastuzumab-related cardiotoxicity JO - Ann Oncol VL - 18 UR - https://doi.org/10.1093/annonc/mdm181 DO - 10.1093/annonc/mdm181 ID - Beauclair2007 ER - TY - JOUR AU - Lu, S. AU - Wang, Z. AU - Liu, H. AU - Hao, X. PY - 2010 DA - 2010// TI - HER2 Ile655Val polymorphism contributes to breast cancer risk: evidence from 27 case–control studies JO - Breast Cancer Res Treat VL - 124 UR - https://doi.org/10.1007/s10549-010-0886-z DO - 10.1007/s10549-010-0886-z ID - Lu2010 ER - TY - JOUR AU - Wang, V. AU - Chuang, T. C. AU - Kao, M. C. AU - Shan, D. E. AU - Soong, B. W. AU - Shieh, T. M. PY - 2013 DA - 2013// TI - Polymorphic Ala-allele carriers at residue 1170 of HER2 associated with Parkinson’s disease JO - J Neurol Sci VL - 325 UR - https://doi.org/10.1016/j.jns.2012.12.017 DO - 10.1016/j.jns.2012.12.017 ID - Wang2013 ER -